BRIEF published on 05/21/2026 at 22:05, 5 months 11 days ago Inventiva at the 2026 Jefferies Global Healthcare Conference Biopharmaceutical Inventiva MASH Lanifibranor Jefferies Conference
BRIEF published on 05/21/2026 at 22:05, 5 months 11 days ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Biopharmaceutical Inventiva Lanifibranor MASH Treatment Jefferies Conference
PRESS RELEASE published on 05/21/2026 at 22:00, 5 months 11 days ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Inventiva to present at 2026 Jefferies Global Healthcare Conference in New York City. CEO Andrew Obenshain to speak on June 3, 2026, about MASH therapies Clinical-Stage Biopharmaceutical Inventiva Lanifibranor 2026 Jefferies Conference MASH Therapies
BRIEF published on 05/13/2026 at 08:35, 5 months 19 days ago Inventiva presents its research on lanifibranor at the EASL Congress 2026 Biopharmaceutical Inventiva MASH Lanifibranor EASL Congress 2026
BRIEF published on 05/13/2026 at 08:35, 5 months 19 days ago Inventiva to Present Abstracts at EASL Congress 2026 Biopharmaceutical Research Inventiva Lanifibranor MASH Treatment EASL Congress 2026
PRESS RELEASE published on 05/13/2026 at 08:30, 5 months 19 days ago Inventiva to Present Abstracts at the EASL Congress 2026 Inventiva to present two abstracts at EASL Congress 2026 highlighting Lanifibranor's impact on MASH treatment. Lanifibranor, a pan-PPAR agonist, shows promising results in clinical trials Clinical Trials Inventiva Lanifibranor MASH Treatment EASL Congress 2026
BRIEF published on 04/22/2026 at 22:05, 6 months 9 days ago Inventiva Bolsters Executive Team as It Nears Key Phase 3 Data Milestone Phase 3 Trial Lanifibranor Leadership Expansion MASH Treatment Inventiva Biopharmaceutical
BRIEF published on 04/22/2026 at 22:05, 6 months 9 days ago Inventiva strengthens its leadership for phase 3 of lanifibranor Appointment Biopharmaceutical Direction Phase 3 Lanifibranor
PRESS RELEASE published on 04/22/2026 at 22:00, 6 months 9 days ago Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor Inventiva strengthens leadership team with new key hires for lanifibranor Phase 3 data readout, bolstering expertise in finance, legal, and HR to drive growth and commercialization Growth Leadership Team Phase 3 Inventiva Lanifibranor
BRIEF published on 04/08/2026 at 22:05, 6 months 23 days ago Inventiva Submits 2025 Financial Reports to AMF and SEC Inventiva 2025 Financial Reports MASH Treatments Biopharmaceutical Developments AMF And SEC Filings
Published on 10/30/2026 at 23:35, 2 days 5 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 5 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 10 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 13 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 18 hours 33 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 1 day ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 12 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 6 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 6 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 11 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 17 hours ago Capital increase through exercise of subscription rights
